Article
Economics
John E. Schneider, Shawn Davies, Maggie Do Valle, Nadine Chami, Paul C. Pagano, David Anderson, Michael J. Donovan
Summary: This study aims to assess the cost-effectiveness of LungLB compared to the current clinical diagnostic pathway (CDP) for patients with indeterminate pulmonary nodules (IPNs) in the US. The results show that using LungLB increases life years and quality-adjusted life years, but also leads to higher costs. The analysis concludes that LungLB, in conjunction with CDP, is a cost-effective alternative for individuals with IPNs in a US setting.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Editorial Material
Economics
Ahmad Z. Z. Al Meslamani, Anan S. S. Jarab, Mohammad A. A. Ghattas
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
Chintal H. H. Shah, Nicole Princic, Kristin A. A. Evans, Bob G. G. Schultz
Summary: The objective of this study was to investigate the trends in paid lanadelumab costs over time in a population of patients persistent for 18 months, and to understand the overall hereditary angioedema (HAE) treatment cost trends, including costs of acute medication/short-term prophylaxis and supportive care. Additionally, the study aimed to determine the proportion of lanadelumab patients with evidence of down titration. The findings showed that patients on long-term prophylaxis with lanadelumab experienced a significant reduction in HAE treatment costs over 18 months, driven by lower costs of acute medications and lanadelumab down titration.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
Stuart Silverman, Elizabeth Packnett, Anthony Zagar, Sheena Thakkar, Patricia Schepman, Warachal Faison, Cory Hultman, Nicole M. Zimmerman, Rebecca L. Robinson
Summary: Higher healthcare costs were observed in Black Medicaid patients with knee/hip osteoarthritis despite lower rates of inpatient admission. These increased costs cannot be attributed to either longer or more frequent hospitalizations; no significant difference in either the length of stay or the number of hospitalizations was observed when comparing Black patients to White patients.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Editorial Material
Economics
J. P. Sevilla
Summary: In the US, RSV poses a significant burden, and currently, only a small percentage of infants have access to immunizations. The monoclonal antibody nirsevimab is a potential solution that has been shown to be safe and effective. The eligibility of passive immunization, like nirsevimab, for federal vaccine programs is being considered. There are strong policy grounds to include passive immunizations, as both active and passive immunizations can have similar effects on population health.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
Maria Mata Lorenzo, Mahmood Ali, Stuart Mealing, Joe Moss
Summary: Through a health economic model, this study evaluates the cost-effectiveness of roxadustat compared to ESAs for treating anemia of non-dialysis-dependent CKD. The model incorporates a hypothetical cohort of 1,000 NDD CKD patients and considers eight different health states representing varying levels of anemia. Results show that roxadustat is on average less costly and more effective than ESAs, with a dominant incremental cost-effectiveness ratio. The model highlights the potential cost-effectiveness and impact of roxadustat in reducing the burden of anemia in NDD CKD patients.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Editorial Material
Economics
Ahmad Z. Al Meslamani
Summary: This article discusses how artificial intelligence (AI) and machine learning (ML) can improve clinical outcomes and reduce economic burdens in asthma care. The study found that AI and ML have the potential to enhance preventive measures, real-time monitoring, and tailored treatment strategies. However, more empirical research is needed to evaluate the cost-effectiveness of AI in asthma care. Additionally, ethical considerations such as data privacy and algorithmic bias are essential for successful integration of AI in healthcare settings.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
Mara Habash, Hannah Guiang, Irvin Mayers, Anna Quinton, Vivian Vuong, Aidan Dineen, Sumeet Singh, Danny Gibson, Adrian P. Turner
Summary: This study aimed to evaluate the cost-effectiveness of adding tezepelumab as a treatment option for severe asthma patients in Canada. The analysis showed that tezepelumab provided additional life years and quality-adjusted life years at an additional cost compared to standard of care.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
Takashi Mizuoka, Hiroyuki Sakamaki, Shigeo Fuji, Shota Saito, Tatsunori Murata, Shinya Ohno, Naoki Inubashiri, Tomoha Oshima, Kazuhito Yamamoto
Summary: The POLARIX trial showed that Pola + R-CHP prolongs progression-free survival in previously untreated DLBCL compared with R-CHOP, with a similar safety profile. This study evaluates the cost-effectiveness of Pola + R-CHP for previously untreated DLBCL from a Japanese public healthcare payer's perspective.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
John A. Carter, Xingyue Huang, Khurram Jamil, Shelby Corman, Varun Ektare, John Niewoehner
Summary: Hepatorenal syndrome (HRS) is a rare and life-threatening complication of the liver that requires immediate treatment with a vasoconstrictive drug. Terlipressin is the most common vasoconstrictor used for HRS patients. This study compared the cost of terlipressin with that of other vasoconstrictors and evaluated their effectiveness in reversing HRS. The results showed that terlipressin had better clinical outcomes and a lower cost per treatment response compared to other unapproved treatments for HRS with rapid reduction in kidney function.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Letter
Economics
Sanjay Hadigal, Laura Colombo, Joseph Cook
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
Roger Lee Mendoza
Summary: This article reviews the medical economics literature presented at the 2023 annual AEA-ASSA convention, focusing on pharmacoeconomic papers. It highlights the common themes and challenges in biopharmaceutical innovation, particularly in terms of discovery and commercialization. The article emphasizes the importance of health policy in ensuring cost reduction, increased access, and quality of pharmacoeconomic solutions.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
Vladislav Berdunov, Ewan Laws, Gebra Cuyun Carter, Roger Luo, Christy Russell, Sara Campbell, Jeremy Force, Yara Abdou
Summary: This study compared the budget impact of using the Oncotype DX test in combination with clinical-pathological risk assessment versus using only clinical-pathological risk assessment in early-stage breast cancer patients. The results showed that using the Oncotype DX test may slightly increase healthcare costs over an initial 5-year period but could lead to significant cost savings beyond this period. Rating: 8 points.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Review
Economics
Tara Cowling, Ransi Nayakarathna, Allison L. Wills, Dipti Tankala, Nancy Paul Roc, Stephane Barakat
Summary: As innovative oncology medicines are being developed, there is pressure on payers to provide timely access to patients. Variations in pathways exist among countries with established health technology assessment frameworks. Understanding these differences may help expedite patient access universally.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
Ibrahim Diakite, Sylvi Nguyen, Ugne Sabale, Andrew Pavelyev, Kunal Saxena, Athar Ali Tajik, Wei Wang, Cody Palmer
Summary: The study aims to evaluate the cost-effectiveness of switching from a bivalent to a nonavalent HPV vaccination program in Norway. The results show that nonavalent vaccination can prevent additional cases of HPV-related cancers, genital warts, and respiratory papillomatosis compared to bivalent vaccination. Although the total costs are higher for the nonavalent strategy, the switch can result in savings in treatment costs.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
Simone Rivolo, Jane Loftus, Balazs Peter, Marion Fahey, Thitima Kongnakorn
Summary: This study evaluated the cost-effectiveness and cost-utility of a once-weekly injectable long-acting human growth hormone (somatrogon) compared to daily injections of recombinant human growth hormone (dGH) for the treatment of pediatric growth hormone deficiency. The results showed that somatrogon treatment led to greater final adult height, higher quality-adjusted life years, and lower overall costs and costs per cm gained compared to dGH.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
Yen Chung, Diego J. J. Maselli, Fan Mu, Erin E. E. Cook, Danni Yang, Joshua A. A. Young, Keith A. A. Betts, Eduardo Genofre, Donna Carstens
Summary: This retrospective study evaluated the economic value of benralizumab in the treatment of severe eosinophilic asthma. The results showed that patients treated with benralizumab experienced a significant reduction in asthma exacerbations, healthcare resource utilization, and medical costs, with the benefits lasting up to 24 months.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
Derek Ebner, John Kisiel, Lianne Barnieh, Rishika Sharma, Nathaniel J. Smith, Chris Estes, Vahab Vahdat, A. Burak Ozbay, Paul Limburg, A. Mark Fendrick
Summary: Initiating average-risk CRC screening at age 45 instead of age 50 reduces disease burden and provides economic cost-effectiveness. Multitarget stool DNA screening is the most beneficial strategy.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
Ekaterina Ponomareva, Luke Schmerold, S. S. S. Srinivas, Ronald Preblick, Seojin Park, Laura Wilson, Andrew Revel
Summary: This study aimed to evaluate the value and affordability of insulin glargine 300 U/mL (Gla-300) from a United States payer perspective. The study found that switching patients from long-acting basal insulins to Gla-300 may reduce healthcare resource utilization and costs, resulting in budgetary savings.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
Mikin V. Patel, Heather Davies, Abimbola O. Williams, Tom Bromilow, Hannah Baker, Stuart Mealing, Hayden Holmes, Nicholas Anderson, Osman Ahmed
Summary: This study compared the cost-effectiveness of transarterial radioembolization (TARE) with two alternative treatments for hepatocellular carcinoma (HCC). TARE was found to be cost-saving compared to conventional transarterial chemoembolization (cTACE) and produced more quality-adjusted life years (QALYs) per person. Although TARE was more expensive than drug-eluting beads chemoembolization (DEE-TACE), it still had a favorable cost-effectiveness ratio. Therefore, TARE is a potentially cost-effective treatment for unresectable early- to intermediate-stage HCC.
JOURNAL OF MEDICAL ECONOMICS
(2023)
